Cataract Senile
Conditions
Brief summary
Evaluation of the clinical safety and effectiveness of hydrophilic acrylic intraocular lens
Detailed description
To show safety and the effectiveness in regard to the monocular corrected distance visual acuity (CDVA), the distance-corrected intermediate visual acuity (DCIVA) and the distance-corrected near visual acuity (DCNVA) at 12-24 month postoperative.
Interventions
OTHERtrifocal lens
not applicable as patients are already implanted with the trifocal lens
Sponsors
Carl Zeiss Meditec AG
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients of any gender, aged 45 years or older at the time of the surgery 2. Patients who had an uncomplicated (no intra-operative complication) aged-related cataract surgery 3. Currently implanted with an the study lens into the capsular bag in at least one eye 4. One-year post surgery follow-up (365 days -14 days/+365 days) for the study eye at the time of the postoperative visit 5. Patient is willing and capable of providing informed consent 6. Patient is willing and capable of complying with visits and procedures as defined by this protocol
Exclusion criteria
1. Preoperative corrected distance visual acuity (CDVA) better than 0.3 LogMAR (0.5 decimal) or CDVA not available preoperatively 2. Preoperative documented endothelial cell count of less than 2000/mm2 (if available) 3. Any preoperative documented ocular disorder that could potentially cause a clinically significant future visual acuity loss 4. Any preoperative documented clinically significant anterior segment pathology (e.g. chronic uveitis, iritis, aniridia, rubeosis iridis, anterior membrane dystrophies, poor pupil dilation, etc.) 5. Any preoperative documented clinically significant abnormal corneal finding (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism, clinically significant corneal membrane dystrophies) 6. Any preoperative documented clinically significant condition that could affect IOL stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, etc.) 7. Any preoperative documented history of clinically significant retinal pathologies or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) that could alter or limit final postoperative visual prognosis 8. Any preoperative acute infection (acute ocular disease, external/internal infection, systemic infection) 9. Any previous preoperative intraocular and corneal surgery 10. Preoperative documented uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment 11. Preoperative documented or current systemic or ocular pharmacotherapy that effects patients' vision 12. Any other preoperative documented or current pathology or condition that could be a risk for the patient according to the investigator opinion 13. Women during pregnancy and/or lactation at time of enrollment into the study 14. Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial 15. Patients whose freedom is impaired by administrative or legal order 16. Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, that do not affect patients' vision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual acuity | 12 to 24 months after the implantation | Visua acuity at far, intermediate and near distances |
Countries
Germany
Outcome results
None listed